The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study.
about
Measures of disability: Arthritis Impact Measurement Scales 2 (AIMS2), Arthritis Impact Measurement Scales 2-Short Form (AIMS2-SF), The Organization for Economic Cooperation and Development (OECD) Long-Term Disability (LTD) Questionnaire, EQ-5D, WorThe National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank.Evolution of direct costs in the first years of rheumatoid arthritis: impact of early versus late biologic initiation--an economic analysis based on the ESPOIR cohort.Factors influencing rheumatologists' prescription of biological treatment in rheumatoid arthritis: an interview study.Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patientsHealth Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohortsTreatment of experimental adjuvant arthritis with a novel folate receptor-targeted folic acid-aminopterin conjugate.Predictors of European League Against Rheumatism (EULAR) good response, DAS-28 remission and sustained responses to TNF-inhibitors in rheumatoid arthritis: a prospective study in refractory disease.Unresolved issues in biologic therapy for rheumatoid arthritis.Biologics-based therapy for the treatment of rheumatoid arthritis.Physician Preferences and Variations in Prescription of Biologic Drugs for Rheumatoid Arthritis: A Register-Based Study of 4,010 Patients in Sweden.Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.Sensitivity and specificity of assesment instruments of quality of life in rheumatoid arthritis.Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.Clinical effectiveness of biologics in clinical practice.Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey.Costs of rheumatoid arthritis during the period 1990-2010: a register-based cost-of-illness study in Sweden.Costs of drugs for treatment of rheumatic diseases.Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials.Assistive devices, home adjustments and external help in rheumatoid arthritis.Pain as an important predictor of psychosocial health in patients with rheumatoid arthritis.Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate.Assessment of the treat-to-target strategy in patients with refractory rheumatoid arthritis. A prospective study on efficacy and safety in a Saudi population.Effect of early treatment on physical function in daily management of rheumatoid arthritis: a 5-year longitudinal study of rheumatoid arthritis patients in the National Database of Rheumatic Diseases in Japan.Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing loss of productivity: the Swedish TIRA project.
P2860
Q26829085-510DDFB6-6418-4CBB-A1C6-0E37432D8ED2Q33452656-CB912B55-F2EA-4A8A-B241-09A4041F3424Q33584199-E059E281-91B6-48D4-B79A-E37B5446B7BFQ34354935-814B4AF5-CADF-4643-848A-A29BD72BEC9BQ34618811-317B7C90-9C09-4A1A-8767-DECD54F6B09FQ34805081-58EF4970-F1A5-4F85-83E6-D0CE1E3C5C21Q35092982-49945E23-5C97-4CEC-9CA2-A618449B0D79Q35577993-41510506-A5B9-470F-B30F-66BFAC31874FQ37851001-04973A8A-BC16-46D2-A899-063B4346A598Q37968143-ECF9D993-EF31-487C-85F4-A64BF174BA4DQ38533964-4D2C5D8D-8CC6-4169-9F51-4529F7A4C609Q38907286-32A89351-F9B2-47A7-AADA-0FEB62B1FAF8Q39850574-4A6289C3-32F7-421F-89D7-0F7A21B19F58Q40813632-485579A3-DFF8-42EC-92DD-C09A29758068Q42748102-5491C2E1-4A88-41F1-919F-B8C57FB2323EQ43461275-BEF221E7-6642-4826-B276-BAAC5C2DE0F8Q44918475-3F583AC5-C079-45C8-8216-666D760BC118Q47164070-594EA9F2-42DF-4486-A5C3-2E62F84F8DEFQ48064243-1479D6FA-CBFB-48AC-8130-5A06A9E3A03CQ48562734-899173C6-5E42-45FC-929B-C50038B28025Q48576983-5D491068-F4FC-44E6-A017-95D1DEA1532BQ50794926-09CB8E4D-BBFE-403E-A3FF-4FD7D9FFF1FDQ51745001-B24873AF-95AE-4EED-8EB0-5558EE98A1ADQ53112047-4B214267-B3EA-4654-A324-127A0D9D7F74Q54417889-0CC33088-4DF0-4AA7-8278-DC813F13BA4B
P2860
The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The loss of health status in r ...... gitudinal observational study.
@ast
The loss of health status in r ...... gitudinal observational study.
@en
type
label
The loss of health status in r ...... gitudinal observational study.
@ast
The loss of health status in r ...... gitudinal observational study.
@en
prefLabel
The loss of health status in r ...... gitudinal observational study.
@ast
The loss of health status in r ...... gitudinal observational study.
@en
P2860
P356
P1476
The loss of health status in r ...... gitudinal observational study.
@en
P2093
Kaleb Michaud
P2860
P2888
P356
10.1186/AR2944
P577
2010-03-02T00:00:00Z
P5875
P6179
1019491559